US › Healthcare

Immunocore Holdings Ltd (IMCR)

US · Healthcare · Biotechnology

$33.24+2.50%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$106.7M
Revenue YoY
+13.6%
Net profit
$13.0M
Profit YoY
+158.2%
EPS
$0.25
EPS estimate
$-0.26
Net margin
12.2%

EPS came in at 0.25 against a street estimate of -0.26 — a beat of 196.2%.

Key statistics

Market cap
$1.72B
Forward P/E
227.3
P/B
4.37
Book value
$7.75
EPS (TTM)
$-0.56
52-week high
$40.71
52-week low
$27.55
50-day MA
$31.16
200-day MA
$32.51
Beta
0.73

Analyst view

Analysts rate Immunocore Holdings Ltd a buy (13 buy, 3 hold, 1 sell out of 17) with an average price target of $63.58.

Shareholding

Insiders
0.07%
Institutions
104.29%

Largest institutional holders

FundStake
RTW INVESTMENTS, LLC9.57%
FMR Inc9.49%
Wellington Management Company LLP9.25%
PRIMECAP Management Company7.26%
Bellevue Group AG5.50%
Vestal Point Capital LP5.44%
TANG CAPITAL MANAGEMENT LLC5.21%
Deep Track Capital, LP3.80%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Immunocore Holdings Ltd — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.